Statin use and fatal prostate cancer: a matched case-control study.
Statin use and fatal prostate cancer: a matched case-control study.
复制标题
DOI：
10.1002/cncr.26720
复制
发表时间：
2012-08-15
期刊：
影响因子：
6.2
通讯作者：
Rhoads GG
中科院分区：
文献类型：
--
作者：
Marcella SW;David A;Ohman-Strickland PA;Carson J;Rhoads GG
他汀类药物是医疗实践中最常用的处方药之一，前列腺癌是最常见的男性恶性肿瘤。虽然没有一致的证据表明他汀类药物影响癌症的发病率，包括前列腺癌，但一些报告表明，他们可能会降低晚期前列腺癌的发病率。然而，没有研究专门研究他汀类药物使用和前列腺癌死亡率。我们在这里报告一个基于人群的病例对照研究，探讨这种关联。我们进行了配对病例对照研究。病例是1997-2000年期间死于前列腺癌的新泽西55 - 79岁的居民。我们按5岁年龄组和种族分别匹配了基于人群的对照组。从盲态病历审查中获得的病例和对照组的药物数据相同。我们使用条件Logistic回归来调整混杂因素。我们确定了718例病例，并获得了77%的配偶（N=553）的合作。在审查医疗记录后，387人符合条件，380人与对照组相匹配。未校正的比值比为0.49（95%CI，0.34-0.70），在校正教育、腰围、BMI、合并症和抗高血压药物后降至0.37（p<0.0001）。亲脂性和亲水性他汀类药物之间几乎没有差异，但与低效力他汀类药物（31%，p=0.32）相比，高效力他汀类药物（73%，p<0.0001）的风险降低更多。他汀类药物的使用与前列腺癌死亡的实质性保护有关，增加了对前列腺癌抑制作用的流行病学证据。
Statins are one of the most commonly prescribed medications in medical practice and prostate cancer is the most common male malignancy. While there has been no consistent evidence that statins affect cancer incidence, including prostate cancer, several reports suggest they may decrease the rate of advanced prostate cancer. However, no study has examined statin use and prostate cancer mortality specifically. We report here a population-based case-control investigation that examines this association. We conducted a matched case-control study. Cases were residents of New Jersey ages 55 – 79 who died from prostate cancer between 1997–2000. We individually matched population-based controls by five-year age-group and race. Medication data were obtained identically for cases and controls from blinded medical chart review. We used conditional logistic regression to adjust for confounders. We identified 718 cases and obtained cooperation from 77% of their spouses (N=553). After review of medical records, 387 were eligible and 380 were matched to a control. The unadjusted odds ratio was 0.49 (95% CI, 0.34–0.70) which decreased to 0.37 (p<0.0001) after adjustment for education, waist size, BMI, comorbidities, and anti-hypertensive medication. There was little difference between lipophilic and hydrophilic statins but more risk reduction was noted for hi-potency statins (73%, p<0.0001) as compared to low-potency statins (31%, p=0.32). Statin use is associated with substantial protection against prostate cancer death, adding to the epidemiologic evidence for an inhibitory effect on prostate cancer.
登录
查看更多内容
影响因子：
10.3
作者：
Platz, Elizabeth A.;Leitzmann, Michael F.;Giovannucci, Edward
通讯作者：
Giovannucci, Edward
影响因子：
3
作者：
Dulak J;Józkowicz A
通讯作者：
Józkowicz A
影响因子：
3.8
作者：
Hoque, Ashraful;Chen, Hongli;Xu, Xiao-Chun
通讯作者：
Xu, Xiao-Chun
影响因子：
5.7
作者：
Marcella, Stephen W.;Rhoads, George G.;Wilcox, Homer
通讯作者：
Wilcox, Homer
DOI：
10.1056/nejmoa0810696
发表时间：
2009-03-26
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andriole GL;Crawford ED;Grubb RL 3rd;Buys SS;Chia D;Church TR;Fouad MN;Gelmann EP;Kvale PA;Reding DJ;Weissfeld JL;Yokochi LA;O'Brien B;Clapp JD;Rathmell JM;Riley TL;Hayes RB;Kramer BS;Izmirlian G;Miller AB;Pinsky PF;Prorok PC;Gohagan JK;Berg CD;PLCO Project Team
通讯作者：
PLCO Project Team